Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

NCT05263817 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05263817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05263817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
October 8, 2021
Completion date
October 1, 2024
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, autoimmune hemolytic anemia, poems syndrome, vasculitis